Time To Revamp Your Online Privacy Disclosures

I hear some version of this from general counsel more often every year: they don't blindly trust their outside firm anymore, they verify it, the same way they verify every other vendor with access to their data. That shift catches a lot of firms off guard. Lawyers see themselves as trusted advisors, but procurement and legal ops teams see a law firm as one more party holding sensitive information. To them, that means proof, not just a handshake.

Canada's privacy regulator has released new draft guidance establishing comprehensive due diligence standards for organizations evaluating third-party service providers under PIPEDA. The framework introduces eleven best practices covering everything from data flow mapping and AI training data sourcing to vendor lock-in risks and ongoing monitoring obligations, signaling heightened expectations for privacy accountability in vendor relationships.

En juin 2026, le gouvernement fédéral a présenté le projet de loi C-36, qui remplacerait la Loi sur la protection des renseignements personnels et les documents électroniques (la LPRPDE) par une nouvelle...

Ce bulletin mensuel a été préparé par le groupe Protection des renseignements confidentiels, vie privée et cybersécurité de Fasken pour vous présenter les actualités et les développements récents qui ont attiré notre attention. Si vous avez des questions sur l’un des sujets abordés dans ce bulletin, communiquez avec l’un des membres de ce groupe, qui se fera un plaisir de vous aider.

The Toronto Regional Real Estate Board’s (TRREB) Q4 2025 Commercial Report records commercial and retail average net lease rates at $29.97 per square foot, up 18.3 per cent year-over-year

This is a monthly bulletin published by the Privacy and Cybersecurity Group at Fasken with noteworthy news and updates. If you have any questions about the items in this bulletin, please contact any member of the Privacy and Cybersecurity Group, and we will be pleased to assist.

Canada's proposed Bill C-36 would fundamentally transform private-sector privacy law by replacing PIPEDA with the Protecting Privacy and Consumer Data Act. Organizations face stricter data collection tests, new consent exceptions, explicit AI governance rules, and penalties reaching $25 million or 5% of global revenue for knowing violations.

In June 2026, the federal government introduced Bill C-36, which would effectively replace the existing Personal Information and Electronic Documents Act (“PIPEDA”) with a new Protecting Privacy...

When does protecting the public justify reaching into an employee's private life?

Canada is often the first international market a US or European company enters, and it is usually the one leadership underestimates. The language is familiar, the legal system outside Quebec is common law, and the commercial culture feels close to home. That familiarity is exactly what makes Canada expensive for companies that treat market entry as an administrative exercise rather than a legal one.

For a Canadian patent application to be examined, an applicant must file a request for examination with the Canadian Intellectual Property Office (CIPO). In most cases, the order in which applications are examined is based on the order that the requests for examination are received. An applicant may be able to accelerate examination of their patent application through several existing mechanisms, including advancing examination via special order, accelerating examination of applications related to green technology, and the Patent Prosecution Highway (PPH).

Le Conseil d'examen du prix des médicaments brevetés (CEPMB) a lancé une consultation supplémentaire de 30 jours sur un projet de directives relatives à la pratique révisées...

Santé Canada a publié de nouvelles modifications réglementaires visant à renforcer sa capacité à prévenir et résoudre les pénuries de médicaments et d'instruments médicaux.

L'Agence des médicaments du Canada établit des principes directeurs pour l'utilisation de l'intelligence artificielle dans la génération de preuves cliniques du contexte réel.

The Patented Medicine Prices Review Board (PMPRB) has launched a second 30-day consultation on revised proposed Practice Directions for hearings related to excessive medicine pricing and compliance with filing requirements. The revised directions incorporate feedback from the initial consultation, with a summary chart detailing all edits available for stakeholder review.

Canada's Drug Agency has released new guidance on using artificial intelligence methods to generate real-world evidence for health technology assessments, establishing governance considerations and appraisal principles that emphasize transparency, human oversight, and validation. The agency also launched initiatives supporting precision medicine decision-making, including testing procedure assessments and a pan-Canadian framework for biomarker evaluation in cancer care.

Health Canada has published comprehensive amendments to drug and medical device shortage regulations, introducing expanded reporting requirements, extended expiration date authorities, and enhanced exceptional importation frameworks. The new measures grant the Minister of Health broader powers to prevent and respond to supply disruptions while requiring manufacturers to provide 12-month advance notice of discontinuations.

Health Canada has announced significant regulatory changes for medical device establishment licensing, set to take effect in December 2026. These Phase II amendments aim to streamline requirements...

Santé Canada modernise son processus d'octroi de licences d'établissement d'instruments médicaux avec des modifications réglementaires majeures entrant en vigueur en décembre 2026. Ces changements visent à alléger le fardeau réglementaire, promouvoir l'innovation et améliorer la compétitivité de l'industrie canadienne des dispositifs médicaux.

Santé Canada a obtenu une injonction permanente contre Canlab Research, interdisant la vente de peptides injectables non autorisés au Canada. Cette décision fait suite à des mesures coercitives répétées visant à protéger les consommateurs contre des produits non homologués présentant des risques graves pour la santé.